| Members |
targetComponentId |
| Myotenoplasty of hand |
Myotenoplasty |
| Myotension technique |
Muscle energy technique (procedure) |
| Myovirus group |
Family Myoviridae (organism) |
| N-b-bis (2-chloroethyl)-2-naphthylamine |
Chlornaphazine (substance) |
| N0 category |
American Joint Committee on Cancer cN0 (qualifier value) |
| N1: Metastasis in 1-3 lymph nodes |
cN1 |
| N1: Metastasis in 1-6 perigastric lymph nodes |
cN1 |
| N1: Metastasis in a single ipsilateral lymph node, < 3 cm in greatest dimension |
cN1 |
| N1: Metastasis in a single lymph node |
cN1 |
| N1: Metastasis in a single lymph node, < 2 cm in greatest dimension |
cN1 |
| N1: Metastasis in a single lymph node, <= 2 cm in greatest dimension |
cN1 |
| N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, including intrapulmonary nodes involved by direct extension of the primary tumor |
cN1 |
| N1: Metastasis in perirectal lymph node or nodes |
cN1 |
| N1: Metastasis in regional lymph node or nodes |
cN1 |
| N1: Metastasis to movable ipsilateral axillary lymph node(s) |
cN1 |
| N1: Metastasis with a lymph node mass less than 2 cm in greatest dimension and 5 or fewer positive nodes, none larger than 2 cm in greatest dimension |
cN1 |
| N1: Pelvic or inguinal lymph node metastasis |
cN1 |
| N1: Regional lymph node metastasis |
cN1 |
| N1: Unilateral metastasis in lymph node(s) > 6 cm in greatest dimension, above supraclavicular fossa |
cN1 |
| N1a: 1-3 nodes involved |
American Joint Committee on Cancer cN1a (qualifier value) |
| N1a: Metastasis in ipsilateral cervical lymph node(s) |
American Joint Committee on Cancer cN1a (qualifier value) |
| N1a: Metastasis in single regional lymph node |
American Joint Committee on Cancer cN1a (qualifier value) |
| N1a: Only micrometastasis, none > 0.2 cm in greatest dimension |
American Joint Committee on Cancer cN1a (qualifier value) |
| N1b: 4-7 nodes involved |
American Joint Committee on Cancer cN1b (qualifier value) |
| N1b: Metastasis in bilateral, midline, or contralateral cervical or mediastinal lymph node(s) |
American Joint Committee on Cancer cN1b (qualifier value) |
| N1b: Metastasis in multiple regional lymph nodes |
American Joint Committee on Cancer cN1b (qualifier value) |
| N1b: Metastasis to lymph node(s), any > 0.2 cm in greatest dimension |
American Joint Committee on Cancer cN1b (qualifier value) |
| N1c: >7 nodes involved |
cN1c |
| N2 category |
cN2 |
| N2: Bilateral metastasis in lymph node(s) > 6 cm in greatest dimension, above supraclavicular fossa |
cN2 |
| N2: Metastasis in 4 or more lymph nodes |
cN2 |
| N2: Metastasis in 7-15 perigastric lymph nodes |
cN2 |
| N2: Metastasis in a single ipsilat lymph node >3cm but <6cm in greatest dimension; or in multiple ipsilat lymph nodes, none >6cm in greatest dimension; or in bilat or contralat lymph nodes, none >6cm in greatest dimension |
cN2 |
| N2: Metastasis in a single lymph node, > 2 cm but <= 5 cm in greatest dimension, or multiple lymph nodes, none > 5 cm in greatest dimension |
cN2 |
| N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) |
cN2 |
| N2: Metastasis in more than one regional lymph node |
cN2 |
| N2: Metastasis to ipsilateral axillary lymph node(s) fixed to one another or to other structures |
cN2 |
| N2: Metastasis to unilateral internal iliac and/or inguinal lymph node(s) |
cN2 |
| N2: Metastasis with a lymph node mass >2 cm but <= 5 cm in greatest dimension, or more than 5 nodes positive, none > 5 cm; or evidence of extranodal extension of tumor |
cN2 |
| N2a: Metastasis in a single ipsilateral lymph node, > 3 cm but < 6 cm in greatest dimension |
American Joint Committee on Cancer cN2a (qualifier value) |
| N2b: Metastasis in multiple ipsilateral lymph nodes, none > 6 cm in greatest dimension |
cN2b |
| N2c: Metastasis in bilateral or contralateral lymph nodes, none > 6 cm in greatest dimension |
cN2c |
| N3 category |
cN3 |
| N3: Metastasis in >15 perigastric lymph nodes |
cN3 |
| N3: Metastasis in a lymph node > 5 cm in greatest dimension |
cN3 |
| N3: Metastasis in a lymph node > 6 cm in greatest dimension |
cN3 |
| N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene or supraclavicular lymph node(s) |
cN3 |
| N3: Metastasis in lymph node(s) |
cN3 |
| N3: Metastasis to ipsilateral internal mammary lymph node(s) |
cN3 |
| N3: Metastasis with a lymph node mass > 5 cm in greatest dimension |
cN3 |
| N3a: > 6 cm in dimension |
cN3a |
| N3b: extension to supraclavicular fossa |
American Joint Committee on Cancer cN3b (qualifier value) |
| NAD(P)H dehydrogenase (FMN) |
NAD(P)H dehydrogenase (quinone) |
| NX category |
cNX |
| Nabothian follicles on cervix |
Mucous retention cyst of cervix uteri (disorder) |
| Nabothian follicles on cervix |
Mucous retention cyst of cervix uteri (disorder) |
| Nabothian follicles on cervix |
Mucous retention cyst of cervix uteri (disorder) |
| Nabumetone 500mg dispersible tablet |
Nabumetone 2.5 mg/mL oral solution |
| Nail dystrophy resulting from poisonous chemical |
Nail dystrophy caused by chemical |
| Nail flap |
Flap (substance) |
| Nairobi sheep disease serogroup |
Nairobi sheep disease virus |
| Nape of neck flap |
Flap (substance) |
| Naphazoline hydrochloride + polyvinyl alcohol + zinc sulfate 0.02%wv/0.25%wv/0.25%wv drops |
Product containing only naphazoline and polyvinyl alcohol and zinc sulfate (medicinal product) |
| Naproxen 200mg/pseudoephedrine 120mg m/r tablet |
Product containing only naproxen and pseudoephedrine (medicinal product) |
| Naproxen 200mg/pseudoephedrine 120mg prolonged-release oral tablet |
Product containing only naproxen and pseudoephedrine (medicinal product) |
| Naproxen 500mg m/r tablet |
Product containing precisely naproxen 500 milligram/1 each gastro-resistant oral tablet (clinical drug) |
| Naproxen sodium 220mg/pseudoephedrine 120mg m/r tablet |
Product containing only naproxen and pseudoephedrine (medicinal product) |
| Naproxen sodium 220mg/pseudoephedrine 120mg prolonged-release oral tablet |
Product containing only naproxen and pseudoephedrine (medicinal product) |
| Naproxen sodium 375mg gastro-resistant oral tablet |
Product containing precisely naproxen 375 milligram/1 each gastro-resistant oral tablet (clinical drug) |
| Naproxen sodium 375mg m/r tablet |
Product containing precisely naproxen 375 milligram/1 each gastro-resistant oral tablet (clinical drug) |
| Naproxen sodium 500mg gastro-resistant oral tablet |
Naproxen only product in oral dose form |
| Naproxen sodium 500mg m/r tablet |
Naproxen only product in oral dose form |
| Narrow open angle |
Narrow angle (finding) |
| Nasal cavity and ethmoid sinus TNM finding |
American Joint Committee on Cancer allowable value |
| Nasal diagnostic laryngoscopy |
Nasal laryngoscopy |
| Nasal flap |
Flap (substance) |
| Nasalis flap |
Flap (substance) |
| Nasolabial flap |
Flap (substance) |
| Nasopharyngoscopy: [diagnostic NEC] or [NEC] |
Nasopharyngoscopy |
| Nasopharynx TNM finding |
American Joint Committee on Cancer allowable value |
| Nausea |
Nausea (finding) |
| Near complete invasion of mesorectum by tumor |
Mesorectal specimen nearly completely intact (finding) |
| Neck of other metacarpal |
Neck of metacarpal bone structure (body structure) |
| Neer 2 part fracture |
Neer two-part fracture |
| Neer 3 part fracture |
Neer three-part fracture |
| Neer 4 part fracture |
Neer four-part fracture |
| Negroid nose |
Nose finding |
| Neisseria meningitidis group Z' |
Neisseria meningitidis serogroup Z (organism) |
| Neisseria meningitidis serogroup D |
Neisseria meningitidis |
| Neomycin sulfate 0.5% conventional release eye drops |
Product containing only neomycin in ocular dose form (medicinal product form) |
| Neomycin sulfate 0.5% single-use eye drops |
Product containing only neomycin in ocular dose form (medicinal product form) |
| Neomycin sulfate allergy |
Allergy to neomycin (finding) |
| Neomycin+hydrocortisone 0.5%/1.5% ear drops |
Hydrocortisone 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL ear solution |
| Neonatal calf diarrhea coronavirus |
Bovine coronavirus (organism) |
| Neonatal candida infection |
Neonatal candidiasis (disorder) |
| Neonatal candidiasis of mouth |
Neonatal candidiasis (disorder) |
| Neonatal death of female (within 4 weeks, United States of America) |
Early neonatal death |
| Neonatal death of female (within 7 days, World Health Organization) |
Early neonatal death |
| Neonatal death of male (within 4 weeks, United States of America) |
Early neonatal death |
| Neonatal death of male (within 7 days, World Health Organization) |
Early neonatal death |
| Neonatal disorder caused by toxic substance transmitted breast milk |
Neonatal disorder caused by substance transmitted via breast milk |
FHIR